The Peptides That Target How You Age — Not Just How You Look

There is a distinction worth making at the outset of any serious conversation about longevity medicine, and it is one that separates the physicians doing genuinely sophisticated work from those offering wellness-adjacent services with longevity branding.

Anti-aging medicine, broadly defined, tends to focus on how aging looks — the visible manifestations of time in the face, the body, and the energy level of a person in their 40s or 50s. Longevity medicine, as the field has developed through the research of the last decade, targets something deeper: the biological mechanisms through which aging actually occurs, measured not by appearance but by molecular markers of cellular function, mitochondrial health, inflammatory burden, and epigenetic drift.

In 2023, a landmark paper by Lopez-Otin and colleagues in the journal Cell identified twelve distinct hallmarks of biological aging — the molecular processes through which organisms age — and gave longevity researchers a precise map of targets: what drives aging at the cellular level, and which interventions act on which hallmarks. Peptide therapy, in the hands of a physician who understands this framework, moves from a collection of optimization tools into a precise targeting system for specific mechanisms of biological decline.

At My Concierge MD in Beverly Hills, Dr. David Nazarian, board-certified in Internal Medicine with deep expertise in longevity medicine and hormone optimization, incorporates the most current evidence-based peptide protocols into a comprehensive longevity program that addresses biological aging — not just its cosmetic expressions.

Biological Age vs. Chronological Age: Why the Distinction Matters

The first thing to understand about longevity peptide therapy is that the goal is not to make a 55-year-old look 40. It is to reduce the biological age of their tissues, measured by the molecular markers that actually predict health trajectory and mortality risk, closer to what a healthy 40-year-old’s markers would show.

Biological age — measured through tools including DNA methylation clocks like GrimAge and DunedinPACE, inflammatory biomarker panels, IGF-1 and growth factor profiles, and mitochondrial function assessments — often diverges significantly from chronological age. Two patients of the same chronological age can show biological age differences of ten to fifteen years based on genetics, lifestyle history, stress burden, and the degree to which they have or haven’t supported their cellular repair systems.

The clinical significance is substantial: biological age acceleration as measured by GrimAge and GrimAge2 has been validated in peer-reviewed research as a meaningful predictor of mortality risk, independent of chronological age. Reducing biological age isn’t a metaphor. It is a clinically meaningful shift in the patient’s health trajectory.

The Mitochondrial Connection — and the Peptides That Target It

Among the twelve hallmarks of aging, mitochondrial dysfunction occupies a specific and critical role. Mitochondria are the energy-producing organelles of every cell, and their progressive decline — the reduction in number, efficiency, and repair capacity that accumulates with age — is associated with virtually every major age-related condition: cardiovascular disease, metabolic dysfunction, neurodegenerative disease, sarcopenia, and reduced immune competence.

Two emerging longevity peptides are specifically targeted at mitochondrial function and represent some of the most compelling findings in the 2025-2026 peptide research literature.

SS-31 (Elamipretide): A mitochondria-targeted peptide that localizes to the inner mitochondrial membrane and stabilizes cardiolipin, a phospholipid critical to mitochondrial structure and electron transport chain efficiency. In aged animal models, SS-31 has reversed functional deficits associated with aging — frailty measures, cardiac strain, skeletal muscle fatigue — in ways that suggest genuine mitochondrial rejuvenation. A 2025 research finding added important nuance: while SS-31 reversed these functional deficits, it did not alter DNA methylation clocks or gene expression signatures associated with biological age. This suggests that mitochondrial dysfunction and epigenetic aging are semi-independent hallmarks — and that SS-31 addresses one without necessarily addressing the other. The implication for clinical practice is that optimal longevity protocols likely require addressing multiple hallmarks simultaneously, not targeting mitochondria in isolation.

MOTS-c: A 16-amino acid peptide that is itself encoded by the mitochondrial genome — part of a newly characterized class called mitochondrial-derived peptides (MDPs). MOTS-c regulates nuclear gene expression related to energy metabolism and glucose homeostasis, functioning as a metabolic reset signal that declines with age. Its roles in regulating insulin sensitivity, exercise adaptation, and cellular stress response make it one of the most biologically interesting emerging peptides in the longevity space. Search interest in MOTS-c is growing rapidly as mitochondrial research enters mainstream health consciousness, and its unique origin — produced by the mitochondria themselves — distinguishes it mechanistically from synthetic peptides.

Growth Hormone, Aging, and the Secretagogue Approach

Growth hormone declines approximately 15% per decade beginning in early adulthood, with the most significant consequences for tissue repair, body composition, sleep architecture, immune function, and metabolic rate becoming apparent in the 40s and 50s. By age 60, many adults have growth hormone profiles that differ meaningfully from their peak, with downstream consequences in every tissue that relies on IGF-1 signaling for maintenance and repair.

The secretagogue approach — using peptides like CJC-1295, ipamorelin, and sermorelin to stimulate physiologic growth hormone release rather than administering exogenous GH directly — offers several advantages in the longevity context. It preserves the natural pulsatile rhythm of GH release rather than producing the supraphysiologic peaks associated with direct GH administration. It maintains the feedback regulation that prevents overstimulation. And it leverages the body’s own pituitary function, supporting rather than replacing an endogenous system.

The combination of CJC-1295 with ipamorelin has become one of the most established protocols in physician-supervised longevity medicine. CJC-1295 stimulates growth hormone release through the GHRH receptor; ipamorelin amplifies that release through the ghrelin receptor. Their mechanisms are synergistic and complementary, producing a more robust and sustained improvement in growth hormone and IGF-1 than either compound alone, while ipamorelin’s selective mechanism avoids the cortisol and prolactin elevations that characterized earlier secretagogues.

The Inflammatory Hallmark — BPC-157 and Tissue Repair

Chronic inflammation — what longevity researchers call “inflammaging” — is recognized as one of the most pervasive drivers of biological aging, contributing to virtually every age-related disease through sustained low-grade activation of inflammatory pathways that progressively damage tissue and impair cellular function.

BPC-157, with its proposed effects on growth factor signaling, nitric oxide modulation, and gut-brain axis communication, represents an intervention point for the tissue repair and anti-inflammatory dimensions of aging. The research literature now exceeds 180 publications, documenting effects across muscle, tendon, gastrointestinal, and neurological tissue in preclinical models. While human clinical data continues to develop, the mechanistic evidence is substantial enough that physician-supervised protocols incorporating BPC-157 are increasingly standard in serious longevity practices — particularly for patients managing chronic injury burden, post-surgical recovery, or the general tissue repair impairment that accumulates with age.

The Case for Combining Peptide Protocols With Biological Age Testing

One of the most significant trends in longevity medicine in 2026 is the integration of biological age testing as a baseline and outcome measurement tool alongside peptide protocols. Rather than evaluating peptide therapy based on subjective reports of improved energy or recovery — which are real but imprecise — biological age measurement provides objective markers that can demonstrate whether the interventions are producing the molecular-level changes they are designed to produce.

At My Concierge MD, Dr. Nazarian’s executive physical assessment — which forms the foundation of the practice’s longevity program — includes the advanced laboratory work that establishes this biological baseline: IGF-1, inflammatory markers, hormonal status, metabolic function, and where indicated, epigenetic age assessment. This baseline allows peptide protocols to be calibrated to individual physiology rather than applied generically, and it creates the measurement framework for tracking whether the interventions are working in the ways that matter most.

This data-driven approach to longevity medicine is what distinguishes a genuine clinical program from a wellness service that borrows longevity terminology. The monitoring is how you know the protocol is doing what you’re asking of it.

Your Longevity Protocol Starts With a Consultation

Longevity peptide therapy at My Concierge MD is not a product. It is a clinical program built around a thorough evaluation of where you are biologically, an evidence-based protocol designed for your specific physiology and goals, and the ongoing physician relationship that monitors outcomes and adjusts over time. Dr. Nazarian and the My Concierge MD team serve patients in Beverly Hills and throughout Los Angeles, with house call availability for patients who prefer care at their location.

Our office is located at 9301 Wilshire Boulevard, Suite 405A, in Beverly Hills. Call (310) 299-8959 to schedule your longevity consultation. The biology of how you age is not fixed — it is a target, and the right protocol makes a measurable difference.